Here I’ll do you one better. “The Plains of

New Post Public Reply Private Reply Replies (1) Message Board
Riztheinvestor sean007 #135574
806

Here I’ll do you one better.

“The Plains of Hesitation.

I've been thinking about all of my investments over the last three decades and most recently within the last two decades, my experience with investing in the biotech space. Because of this experience, I want to share with new or young investors what I've found to be the good, the bad and the ugly about biotech investing. I can't possibly cover everything but, want to touch on just a few. Some will call it conspiracies but, it's not a conspiracy if it's true and I have plenty of examples, not anecdotal fluff.

First, my reasons why? Thirty years ago, the technology to share information, as we know it today did not exist. The Internet was just coming out of its infancy into the market. It had always been part of the US Defense technology, spearheaded by the Defense Advanced Research Projects Agency (DARPA), but was not available to the masses. I still remember the commentary in the news that this couldn't work, for many reasons but at the time because home computing had just got off the ground in the 1980s and dial up modems were the only connection, combined with bytes at low levels and processors being first iterations, i.e.; "The Intel" 16 bit processors. I was happy getting my first Hewlett Packard that ran on 64 bits, and upgraded to 128 bits when I purchased it from Circuit City. It was the shizzle! Apple phones weren't what you carried, rather flip phones, Blackberry phones or satellite phones. My pager was more valuable to me at the time than my computer. So, wrapping this paragraph up, nobody could share their experience with you unless you read the ticker in the paper the next day, heard from a friend or took advice from your broker.

Now, the meat and potatoes.
The Bad! In my personal humble opinion, the bad is lead by the bureaucracy at the FDA. Honestly, they have put such a bad taste in my mouth after watching what they do to small research and development companies with "unproven" promising technology. The wheels turn at turtle speed, they give advice on clinical trial design that is either unwarranted, later disregarded or rejected by the next level of FDA oversight as not being rigorous enough, lacks population size i.e.; (demographics), moved the goal posts, now want more than ABC and want ABCDEFG, out of the blue ask for comparisons to biomarker groups to determine if improved outcomes can be demonstrated, etc. You get the picture. Worst of all, it can happen at any phase of trials along what is already a 10-13 year journey for drug approval! Over the course of time, the share price rises on approvals and can drop on news of more FDA delays. Yes, they serve a purpose and I'm not saying they are at fault. Just bringing it out into the light for new biotech investors what typically awaits them. The longer the research takes, the more delays are likely to occur thus, the lower the SP can go.

The second "bad", if you can imagine this is Wall Street. Can't say I have firsthand relationships with the ilks of people such as Martin Shkreli, but we have plenty of examples of bad actors who for one reason or the other have taken overt actions to destroy biotechs. Martin Shkreli, you may know him as "Pharma Bro" but, before his involvement with buying a pharma and raising prices, he ran his own hedge fund. He personally would write a persuasive argument against a drugs approval and send the letters to the FDA ADCOM committee hearings before voting on whether to move forward with a drugs approval. He would hold a large short position in a company and for dubious reasons, execute a plan to destroy the wealth of shareholders, catch and kill new technology and smile at you with that smug face while hiding behind his veil of lies and deceit. He finally was convicted and sent to prison, although out now, for his lack of moral character and deceit.

If the cards aren't already stacked against you in this space with two "bad" concerns, I'll add a third. There are behemoth large cap pharmaceutical players ($200B+) who spend billions of dollars to buy small companies in order to further their science, whether infectious diseases, medical devices, oncology, transplants, and the various sub-research categories such as stem cell, CAR-T, mRNA/DNA, mAbs, etc and on marketing and sales in order to drive out competition, keep market share and prevent the paradigm shifting new drug/technology from either cannibalizing their products and to dampen any threat they perceive as creative destruction. They're directly in competition with each other and small cap biotech research companies are collateral damage in the crossfire.

The Ugly! Research and Development companies are not typically flush with cash. In fact, frequent fund raising is a huge part the CEOs goals. They travel all over the United States and will get 10-15 minutes to do a presentation in order to expose institutional investors to the XYZ "story" that is their brand, pipeline, discoveries, current assets, and people of XYZ Biotech. Not so bad, right? Whether through dilution, credit facilities, issuance of convertible debt/bond instruments and the like, these efforts while necessary, can adversely impact your investment. A lot of the time spent at these healthcare conferences for early stage biotech's is spent on finding a source, book maker, a financial institution that specializes in providing finance options to the CEO, who will later transact a share offering ( or some other instrument) and in return, the book makers profit from the deal. It's a never ending death by a thousand cuts of toxic financing that typically damages the share price.

So, several examples that create wealth destruction for biotech investors; Delays by the FDA, WS greed, large cap pharmaceuticals preserving their stranglehold on the market and toxic finance deals. Can there be any good left? What have I learned that leads me to the good? Well, to start, I try to navigate and circumvent around, over and under all of the bad. First, I never buy for the long term into a biotech that is just starting out. The novelty of their ideas generates a large swell of interest at the beginning. Once the honeymoon affect wears off, the slow walk down into the death spiral begins. While that sounds bad, it is usually for these who bought into the hype at the beginning. While WS is profiting off deals, running up SP and creating FOMO, they drag it back down. Buyers lose interest, algorithms takeover and before you know it, you are trading on the OTC in decimals out to one thousand.

But, what if you found a company that has been in existence for decade(s), suffered through all of the bad (outlined above) either through self-affliction, poor corporate oversight, poor fiscal management, unsound accounting principles, FDA delays, sabotage, etc. yet they owned a drug that is well established in the medical community, the drug's safety profile was well-known and supported with volumes of publications, clinical trials were well underway and results showed promise and most, if not all of the suffering over a decade that happened to early investors was years and years out of your way? As a bonus, the ridiculous "once in a life time" share price is still at rock bottom prices? Relatively speaking, this has been in the ball park below one dollar since January 2022 with the exception of a brief 5 day run up in late July-early August 2022.

Do you scoff at the opportunity, still concerned with the "Bad and the Ugly," when I detailed for you who, what, when, why and how transformative biotechs with promising technology find themselves in such a demise? If you just discovered CYDY, you are one lucky investor. Their drug, Leronlimab is a blockbuster drug with such attention by those I've described above. I implore you to do the research on every thing I've said. Join chat groups, GOOGLE "Leronlimab" and "CCR5" and learn the method of action of this drug and, read why HIV positive patients such as Charlie Sheen have publicly stated this drug aka PRO140 saved their lives. If you read all of this and find yourself asking "Do I go ahead and toss some money here or do I wait", I share with you this favorite quote of mine, "Upon the plains of hesitation bleached the bones of countless millions who sat down to wait..and while waiting, they died. (Anonymous)

Pardon any grammatical or spelling errors. Give the old guy a break!

​”

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tragedy Highlights Need for E-bike Safety Overhaul

Updated Category News Views 3

A Dire Wake-Up Call in the East Village We're staring hard at a heartbreaking mess in the East Village. A 15-year-old girl lost her life while riding an electric Citi Bike, hit by an industrial truck. Let's not dance around it—this is a gut punch, the kind you never want to ever hear about, and one that comes with a bitter flavor of 'what if?' Age Verification: A...

Continue Reading
Papa John's Faces Class Action Over Misleading Info

Updated Category News Views 0

Trouble Brewing for Papa John's Investors Rolling the dice in the stock market sometimes feels like playing the lottery, doesn't it? This time around, it's Papa John's (NASDAQ: PZZA) serving up a slice of turmoil for its investors. The pizza chain's got itself tangled in a class-action lawsuit, and it's the shareholders who're left with a bitter taste. Investors Cry Foul...

Continue Reading
Beta Bionics Lawsuit Deadline: Investors Face November 3 Cut-off

Updated Category News Views 4

Looming Deadline for Beta Bionics Investors Time's ticking fast for those holding onto Beta Bionics (BBNX) stock who might've been caught in a web of undisclosed risks and regulatory misses. Investors feeling the pinch from this fiasco have till November 3, 2026, to throw their hat in the ring as lead plaintiffs in the class action lawsuit out of California. The...

Continue Reading
Shanghai's Arts Carnival Fuses Tech and Culture

Updated Category News Views 2

Shanghai Heralds New Era in Arts with Carnival Coming in hot, Shanghai's ready to shake up the city's cultural scene with the 2026 International Audio-Visual Arts Carnival. It's happening in Jing'an District from September 24 to October 18, promising an experience that fuses travel, technology, and art. Just about anyone can catch a break from their daily grind and dive...

Continue Reading
Insta360 Expands with Times Square Flagship Store

Updated Category News Views 3

Insta360 Times Square Opening Marks Bold Expansion I dropped by Times Square today, and what do I see? Insta360 planting its flag right in the heart of New York City. Now, this isn't your run-of-the-mill grand opening—it’s the first flagship store outside of Asia, and it screams of big ambitions. Nestled at 1515 Broadway, the store is smack in the middle of one of the...

Continue Reading
Flying Car Regulatory Sandbox Begins in UAE

Updated Category News Views 3

Pioneering Flying Cars in the Desert In a move that seems right out of a science fiction screenplay, ARIDGE—the bigwig of flying cars from Asia—has taken a giant leap. They’ve cozied up with the UAE, locking arms to cook up the world's first regulatory sandbox for personal flying cars. Now, don’t laugh—sandbox isn't just for toddlers. It’s the playground where...

Continue Reading
Why Liver Nurture Taps into Health Sector Trends

Updated Category News Views 2

Liver Wellness: A Sector on the Rise Remember when everyone was all about heart health and cholesterol levels? Seems like these days, folks have shifted their focus a bit south—right to the liver. It's no surprise, really. With our modern diet and lifestyle choices squeezing the life out of this hard-working organ, people are on the hunt for ways to give it the TLC it...

Continue Reading
Med Spa Visits: Key Insights from Lindsey Smith

Updated Category News Views 3

Moving Beyond the Fear Factor Stepping into a med spa for the first time can be nerve-wracking, especially if you're unsure of what to expect. Lindsey Smith, an expert from Flawless Med Spa in Bryant, Arkansas, knows just how critical it is to navigate this terrain with clarity. Her approach emphasizes building a foundation of trust and understanding from the get-go. Fear...

Continue Reading
USPS Rolls Out Christmas Cookie Stamps Nationwide

Updated Category News Views 2

USPS Delivers Nostalgia with Cookie-Themed Stamps Let's talk stamps, folks. The U.S. Postal Service has rolled out its newest Christmas Cookies Forever stamps, bringing a dash of sugary nostalgia to mailboxes nationwide. The release was celebrated at the Smithsonian National Postal Museum, spotlighting a tradition as sweet as the sugar cookies themselves. These aren't...

Continue Reading
Qatar Foundation Spurs Sport-Driven Empowerment Moves

Updated Category News Views 1

Here we go, diving into the serious talk of the moment: sports pushing boundaries to uplift society's underdogs. Envision yourself in the halls of Wilton Park, where the thinkers, the dreamers, and the doers convened in the name of change. Qatar Foundation ain't just sitting pretty; they're championing the cause to harness sport for impactful social threads across the...

Continue Reading

Top 5 Most Recently Viewed Articles

Essential Winter Preparation Tips from Quality Heating Experts

Updated Category News Views 87

Essential Winter Preparation Tips from Quality Heating Experts Tulsa home service experts share maintenance tips to help families stay safe and comfortable during winter. Quality Heating, Cooling, Plumbing & Electric, a prominent service provider in HVAC, plumbing, and electrical solutions, emphasizes the necessity of preparing your home for the winter months. The...

Continue Reading
Adecoagro S.A. Achieves Impressive Financial Growth in 2024

Updated Category News Views 216

Adecoagro S.A.: Outstanding Financial Results for the Year Adecoagro S.A. (NYSE: AGRO), a notable leader in sustainable agricultural production, has reported remarkable financial results for 2024. The company showcased adjusted EBITDA of $444 million and NCFO of $161 million, despite facing operational challenges in the market. Main Financial Highlights In 2024, Adecoagro...

Continue Reading
Exciting Consumer Trends You Shouldn't Miss This Week

Updated Category News Views 356

This Week's Consumer News Highlights With the consumer goods landscape changing rapidly, it can be tough to keep up with the latest innovations and news. This week brings a flurry of exciting announcements from various brands, introducing fresh flavors, innovative designs, and enticing offers that are bound to appeal to shoppers. Let's dive into the top stories shaping...

Continue Reading
BC.GAME Strengthens Global Compliance for Future Growth

Updated Category News Views 198

BC.GAME's Strategic Compliance Enhancement BC.GAME, a premier cryptocurrency i-Gaming platform, has taken a significant step by withdrawing its gaming license from Curaçao. This decision is a bold reflection of the evolving dynamics within the global gaming sector, particularly highlighting the challenges that operators face in Curaçao due to its outdated legal...

Continue Reading
Alliant Insurance Services Rebrands FutureSense to Enhance HR Solutions

Updated Category News Views 100

Alliant Insurance Services Rebrands FutureSense as Alliant Human Capital IRVINE, Calif. — Alliant Insurance Services has officially rebranded FutureSense, LLC as Alliant Human Capital, marking a significant evolution in HR consulting. This strategic decision reflects Alliant's commitment to enhancing its capabilities across various industries and regions, demonstrating...

Continue Reading